01 February 2023>: Lab/In Vitro Research
Neutrophil-to-Platelet Ratio in Patients with Ulcerative Colitis Treated with Infliximab or Vedolizumab: A Retrospective, Single-Center Study in Poland
Marcin Warpechowski 1CD* , Jędrzej Warpechowski 2AEF , Anita Pieńkowska 2BEF , Szymon Sagała 2BEF , Robert Milewski 1CDEDOI: 10.12659/MSM.938827
Med Sci Monit 2023; 29:e938827
Figure 5 A receiver operating characteristic curve was used to analyze the predictive ability of neutrophil-to-platelet ratio in patients treated with vedolizumab during the induction phase (weeks 2, 6, 14); AUC=0.795; 95% CI: 0.559–1; AUC – area under the curve, CI – confidence interval. The figure was created using Statistica version 13 (TIBCO Software, Inc.).